Apogee Therapeutics' Mid-Stage Trial Boosts Shares

On this episode of Stock Movers:

- Apogee Therapeutics (APGE) soars after the drug developer provided maintenance data from a mid-stage trial that showed its experimental therapy deepened responses in patients with moderate-to-severe atopic dermatitis.

- Synopsys (SNPS) shares gain following reports that activist investor Elliott Investment Management has made a multibillion-dollar investment in the chip-design software company.

- Norwegian Cruise (NCLH) shares rose. Cruise companies traded higher in response to a decline in the cost of oil.

See omnystudio.com/listener for privacy information.